Brigatinib

Brigatinib (AP26113) (by Ariad) (breakthrough status in U.S.) (also an EGFR inhibitor)

Brigatinib, a next-generation ALK inhibitor, shows promising activity in Anaplastic lymphoma kinase non small cell lung cancer that have previously received crizotinib with response rates in ALTA ranging from 42-50%, intracranial response 42-67% and median progression-free survival 9.2-12.9 months. Randomized Phase III trial, ALTA-1 L is investigating brigatinib in ALK inhibitor-naive patients ¹⁾.